Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Quality Of Life in Prostate Cancer Patients Initiating Triptorelin (QOCPIT)

16 november 2026 bijgewerkt door: Ipsen

QOCPIT (Quality Of Life in Prostate Cancer Patients Initiating Triptorelin): A Prospective Observational Study to Evaluate Baseline Factors That Stabilize or Improve Health-related Quality of Life.

Prostate cancer and its treatment, particularly androgen deprivation therapy (ADT) may affect different aspects of a person's quality of life, including physical well-being and daily activities.

The purpose of this study is to evaluate baseline factors that stabilize or improve quality of life in patients with prostate cancer who are initiating triptorelin treatment as ADT, in routine clinical practice.

Participants in this study will be patients with prostate cancer whose treating physician has decided to initiate treatment with triptorelin.

This is an observational study. No treatment will be assigned as part of the study, and all medical decisions will be made by the treating physician according to routine clinical practice.

Participants will be followed for approximately 6 months. Information collected during the study may include demographics and medical characteristics, prostate cancer and treatments characteristics, physical activity, supportive care and quality of life. Questionnaires about quality of life and physical activity will be completed by participants at the start of the study and again approximately 6 months later. Information on adverse events occurring during the study will also be collected.

Studie Overzicht

Toestand

Nog niet aan het werven

Conditie

Studietype

Observationeel

Inschrijving (Geschat)

819

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Adult males with prostate cancer initiating triptorelin treatment in routine clinical practice and meeting the study eligibility criteria.

Beschrijving

Inclusion Criteria:

Patients are eligible to be included in the study only if all the following criteria apply:

  1. Males ≥18 years old.
  2. Patient with histologically confirmed PCa.
  3. Patient eligible to start triptorelin in its labelled indication for at least 6 months and for whom the decision to start triptorelin was made voluntarily by the physician as part of routine medical practice, prior to the inclusion in the study.
  4. Patient able to understand and complete study-related questionnaires.
  5. Patient having been informed and not opposed to participating in the study.
  6. Patient covered by healthcare insurance.

Exclusion Criteria

Patients will not be included in the study if they meet any of the following criteria:

  1. Patient currently participating in any interventional clinical trial.
  2. Patient who received a hormonal treatment during the last 6 months before inclusion (or hormonal treatment whose duration of action may impact the 6 months before inclusion).
  3. Patient under tutorship or curatorship; patients under safeguard of justice or deprived of his liberty by an administrative or court decision.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Identification of baseline factors including: demographic, clinical, disease and treatment factors, associated with stabilization (change:]-10; 10[) or improvement (change ≥10) of Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score
Tijdsspanne: At 6 months
At 6 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Participants' baseline demographic characteristics
Tijdsspanne: At baseline

Including:

  • Age.
  • Partnership status.
  • Employment status.
  • Area of residence.
  • Socioeconomic status.
At baseline
Participants' clinical characteristics at baseline
Tijdsspanne: At baseline

Including:

  • BMI
  • Eastern Cooperative Oncology Group (ECOG) Performance status score.
  • G8 score if applicable.
  • Comorbidity status, medical and surgical history, and systemic treatments for comorbidities.
  • Participant's level of physical activity, using IPAQ questionnaire.
At baseline
Prostate cancer characteristics at diagnosis and baseline
Tijdsspanne: At baseline

Including:

  • Prostate Cancer (PCa) presentation (new diagnosis or recurrence/progression) at baseline.
  • Gleason score/International Society of Urological Pathology (ISUP) group
  • TNM (Tumor Node Metastasis) at diagnosis.
  • Prostate Specific Antigen (PSA) and testosterone levels at PCa diagnosis.
  • Previous treatments received for PCa, if any.
At baseline
Participants symptoms at baseline
Tijdsspanne: At baseline
At baseline
Participants' PCa treatment patterns at baseline
Tijdsspanne: At baseline
  • Triptorelin treatment modalities
  • Radiotherapy modalities
  • Associated systemic PCa treatments
At baseline
Participants' healthcare pathway/supportive care done or planned
Tijdsspanne: At baseline

Including:

  • Pretreatment assessments
  • Visits to supportive health care professionals done or planned.
  • Participation in a dedicated healthcare pathway (as a one-day hospital stay with visits to several healthcare professionals).
  • Associated prescriptions or recommendations
  • Complementary information on cancer patient organizations and/or websites.
At baseline
Evolution of PCa at 6-month follow-up according to investigator's opinion
Tijdsspanne: At 6 months

Evolution of PCa at 6-month follow-up according to investigator's opinion: control / stable / progression.

At 6 months
Symptoms and biological characteristics at 6 months
Tijdsspanne: At 6 months
At 6 months
Participant's level of physical activity, using International Physical Activity Questionnaire (IPAQ) questionnaire
Tijdsspanne: At 6 months

The International Physical Activity Questionnaire (IPAQ) is a participant-reported questionnaire used to assess physical activity level. Higher scores indicate higher levels of physical activity.

At 6 months
Participants' Quality Of life (QoL)
Tijdsspanne: At baseline and at 6 months
  • FACT-P total score, sub-scores and individual items, at baseline and at 6- month follow-up, and their changes from baseline.
  • European Organisation for Research and Treatment of CancerQuality-of-Life Questionnaire Prostate Module (EORTC QLQ-PR25) sexual activity individual items and domain scores at baseline and at 6-month follow-up and changes from baseline.
At baseline and at 6 months
Participants' PCa treatment patterns at 6 months
Tijdsspanne: At baseline and at 6 months
  • Collection of triptorelin administrations from initiation
  • Radiotherapy modalities in case of changes,
  • Associated systemic PCa treatments in case of changes.
At baseline and at 6 months
Participants' healthcare pathway/supportive care at 6 months
Tijdsspanne: At 6 months

• Participant's healthcare pathway/type of supportive care in case of changes.

At 6 months
Identification of factors associated with participant's quality of life
Tijdsspanne: At 6 months

• Identification of baseline factors, including demographic, clinical, disease and treatment factors, associated with stabilization (change: ]-3;3[) or improvement (change ≥3) of Physical Well-Being (PWB) and Prostate Cancer Specific (PCS) sub-scores of FACT-P at 6 months after inclusion, using a logistic model.

At 6 months
Percentage of participants with adverse events
Tijdsspanne: From enrollment to Month 6

An adverse event (AE) is any untoward medical occurrence in a participant. The percentage of participants experiencing at least one adverse event, including cardiovascular events occurring after initiation of triptorelin treatment, will be assessed during study follow-up.

From enrollment to Month 6

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Ipsen Medical Director, Ipsen

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

23 november 2026

Primaire voltooiing (Geschat)

25 februari 2028

Studie voltooiing (Geschat)

30 oktober 2028

Studieregistratiedata

Eerst ingediend

16 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 november 2026

Eerst geplaatst (Werkelijk)

20 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

20 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD-tijdsbestek voor delen

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD-toegangscriteria voor delen

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren